NCT03054532View on ClinicalTrials.gov

Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

PHASE2UnknownINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 31, 2017

Primary Completion Date

January 31, 2021

Study Completion Date

July 31, 2021

Conditions
LYMPHOMA
Interventions
DRUG

Durvalumab

Durvalumab intravenous 1500 mg

DRUG

Lenali

Lenalidomide oral 20 mg/day

Trial Locations (4)

119228

National University Hospital Singapore, Singapore

169608

Singapore General Hospital, Singapore

169610

National Cancer Centre Singapore, Singapore

188770

Raffles Hospital Singapore, Singapore

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Singapore General Hospital

OTHER